Technology
Health
Medical

Axonics Modulation

$30.24
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.09 (0.30%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell AXNX and other stocks, options, ETFs, and crypto commission-free!

About

Axonics Modulation Technologies, Inc. operates as a medical technology company, which engages in the design, development, and commercialization of sacral neuromodulation solutions. The firm focuses on the treatment of patients with overactive bladder (OAB), fecal incontinence (FI), and urinary retention (UR). Read More It offers rechargeable SNM system, which delivers mild electrical pulses to the targeted sacral nerve in order to restore normal communication to and from the brain to reduce the symptoms of OAB, FI, and UR. The company was founded by Guang Qiang Jiang, Danny L. Dearen, Timothy Deer, and Michael V. Williamson in March 2012 and is headquartered in Irvine, CA.

Employees
87
Headquarters
Irvine, California
Founded
2012
Market Cap
852.80M
Price-Earnings Ratio
Dividend Yield
Average Volume
158.88K
High Today
$30.43
Low Today
$29.35
Open Price
$29.99
Volume
62.84K
52 Week High
$32.90
52 Week Low
$11.95

Collections

Technology
Health
Medical
2018 IPO
US
North America

News

Yahoo FinanceMay 8

Axonics® Announces First Quarter 2019 Financial Results and Operational Update

146
Yahoo FinanceApr 24

Axonics® to Report First Quarter 2019 Financial Results and Host a Conference Call on May 8

IRVINE, Calif.--(BUSINESS WIRE)-- Axonics Modulation Technologies, Inc. (AXNX), a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, today announced that it will release financial results for the first quarter of 2019 and provide an update on operations and FDA regulatory status after the market closes on Wednesday, May 8, 2019. In conjunction with the release, the Compa...

108

Earnings

-$2.67
-$1.89
-$1.12
-$0.34
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
-$0.47 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.